We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Is President Donald Trump on a Collision Course With History? More Than a Century of Data Paints a Clear Picture. Does Warren Buffett Know Something Wall Street Doesn't? He Just Made a Shocking ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 ...
Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...
Neurocrine Biosciences exceeded earnings expectations ... in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental ...
Neurocrine's Phase 3 pipeline is also set to ... we have that came out of the Phase 2 program and quite frankly, so was Takeda. As we've seen from Takeda over the past several years, they've ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results